107 results
8-K
EX-99.1
MNKTQ
Mallinckrodt plc
26 Mar 24
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
4:01pm
, adjusted R&D expenses, and net sales growth (loss) on a constant-currency basis, which are considered "non-GAAP" financial measures under applicable SEC … -start inventory related expenses; and other items identified by the Company.
Adjusted gross profit, adjusted SG&A expenses and adjusted R&D expenses
8-K
MNKTQ
Mallinckrodt plc
2 Feb 24
Departure of Directors or Certain Officers
8:38am
in healthcare, including business turnarounds and transformations, manufacturing, marketing, engineering, R&D and supply chain. He is currently a Pharmaceutical … (now a Thermo Fisher Scientific company), and President, R&D and Global Manufacturing at Valeant Pharmaceuticals. Earlier in his career, he held
8-K
EX-99.1
ticunnm6 2164
7 Nov 23
Mallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial Results
6:00am
8-K
EX-99.1
7xelt9yc a6blhv4p
21 Sep 23
Independent Experts Report
10:41am
8-K
EX-99.3
894anhe1xxykkby3r2
23 Aug 23
Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan
8:15am
8-K
EX-99.2
tstmcdfacxyhz4 con7
23 Aug 23
Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan
8:15am
8-K
EX-99.1
etfoeiz42yhmpjum
9 Aug 23
Mallinckrodt plc Reports Second Quarter 2023 Financial Results and Reaffirms Full Year Guidance
6:44am
8-K
EX-99.1
619jjaa6n9sakvn 4xf
9 May 23
Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance
6:48am
8-K
EX-99.1
kawtwm9vw shn2vmxp0
8 Nov 22
Mallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms Guidance
6:44am
DEFA14A
6t97rped9fvdzoqq
22 Aug 22
Additional proxy soliciting materials
5:22pm
8-K
EX-99.1
q8abf
11 Aug 22
Mallinckrodt plc Reports Second Quarter 2022 Financial Results
6:01am